aldosterone antagonists in monotherapy are protective against streptozotocin-induced diabetic nephropathy in rats醛固酮拮抗剂在单一疗法预防体外大鼠糖尿病肾病.pdfVIP

Aldosterone Antagonists in Monotherapy Are Protective against Streptozotocin-Induced Diabetic Nephropathy in Rats 1,2 3 4 5 6 1 Nora F. Banki , Agota Ver , Laszlo J. Wagner , Adam Vannay , Peter Degrell , Agnes Prokai , 1,2 1,2 1 1 3 1 Renata Gellai , Lilla Lenart , Dorottya-Nagy Szakal , Eva Kenesei , Klara Rosta , Gyorgy Reusz , 1 1,5 7 1,2 Attila J. Szabo , Tivadar Tulassay , Chris Baylis , Andrea Fekete * 1 1st Department of Pediatrics, Semmelweis University, Budapest, Hungary, 2 SE-MTA ‘‘Lendulet’’ Diabetes Research Group, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary, 3 Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University, Budapest, Hungary, 4 Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary, 5 Research Laboratory for Pediatrics and Nephrology, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary, 6 2nd ´ Department of Medicine and Nephrological Center, Pecs, Hungary, 7 Departments of Physiology and Functional Genomics and Medicine, University of Florida, Gainesville, Florida, United States of America Abstract Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) are the standard clinical therapy of diabetic nephropathy (DN), while aldosterone antagonists are only used as adju